Researchers from the University of Rhode Island are championing a recent breakthrough in the laboratory with hopes it could lead to a vaccine against the pathogen responsible for stomach cancer and to therapeutics for inflammatory diseases.

A study tracing the evolution of HIV in North America has found evidence that the virus is slowly adapting over time to its human hosts. However, this change is so gradual that it is unlikely to have an impact on vaccine design.

Study in Nature shows wide variation in the collection of bacteria harbored by healthy adult.

Scientists at The University of Texas at Austin have discovered that a protein produced by the influenza A virus helps it outwit one of our body's natural defense mechanisms. That makes the protein a potentially good target for antiviral drugs directed against the influenza A virus.

UD researchers demonstrate that processing can affect size of nanocarriers for targeted drug delivery.

Scientists have identified two unlikely partners in a type of immune cell called a macrophage that work together in response to cancer drugs to increase inflammation in a way that may alter tumor growth. Researchers from the National Institutes of Health published the study in the journal Cancer Research.

Johnson & Johnson Innovation is first collaborator.

Scientists reported yesterday (Apr. 10) the first human recipients of laboratory-grown vaginal organs. A research team led by Anthony Atala, M.D., director of Wake Forest Baptist Medical Center’s Institute for Regenerative Medicine, describes in the Lancet long-term success in four teenage girls who received vaginal organs that were engineered with their own cells.

Natural compound from green tomatoes increases muscle, protects against muscle wasting.

OGT’s new whitepaper explores the next stage of molecular testing.